Search

Your search keyword '"Staat, Mary A."' showing total 724 results

Search Constraints

Start Over You searched for: Author "Staat, Mary A." Remove constraint Author: "Staat, Mary A."
724 results on '"Staat, Mary A."'

Search Results

1. Durability of Original Monovalent mRNA Vaccine Effectiveness Against COVID-19 Omicron-Associated Hospitalization in Children and Adolescents - United States, 2021-2023.

2. Effectiveness of Maternal mRNA COVID-19 Vaccination During Pregnancy Against COVID-19-Associated Hospitalizations in Infants Aged <6 Months During SARS-CoV-2 Omicron Predominance - 20 States, March 9, 2022-May 31, 2023.

3. NFKB2 haploinsufficiency identified via screening for IFN-α2 autoantibodies in children and adolescents hospitalized with SARS-CoV-2–related complications

4. Risk factors for health impairments in children after hospitalization for acute COVID-19 or MIS-C.

6. Author Correction: Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C.

8. Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19-Associated Hospitalization in Infants Aged <6 Months - 17 States, July 2021-January 2022.

9. Medical Costs of Respiratory Syncytial Virus–Associated Hospitalizations and Emergency Department Visits in Children Aged Younger Than 5 Years: Observational Findings from the New Vaccine Surveillance Network, 2016-2019

10. Characteristics and Clinical Outcomes of Vaccine-Eligible US Children Under-5 Years Hospitalized for Acute COVID-19 in a National Network

11. Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C

12. Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12-18 Years - United States, June-September 2021.

13. Breastfeeding Disparities and Their Mediators in an Urban Birth Cohort of Black and White Mothers.

14. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season--New Vaccine Surveillance Network, October 2023-February 2024

15. Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness--United States

17. Multi-omics analysis of mucosal and systemic immunity to SARS-CoV-2 after birth

18. Respiratory Syncytial Virus-Associated Hospitalizations in Children &lt;5 Years: 2016–2022

19. Novel paradigm enables accurate monthly gestational screening to prevent congenital toxoplasmosis and more

20. Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination

22. Contributors

23. SARS-CoV-2 Epidemiology and COVID-19 mRNA Vaccine Effectiveness Among Infants and Children Aged 6 Months-4 Years--New Vaccine Surveillance Network, United States, July 2022-September 2023

24. Risk Factors for Multisystem Inflammatory Syndrome in Children: A Case-control Investigation

25. Reemergence of Mycoplasma pneumoniae Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018-2024

26. Accuracy of Influenza ICD-10 Diagnosis Codes in Identifying Influenza Illness in Children

27. Endemic Coronavirus Infections are Associated with Strong Homotypic Immunity in a US Cohort of Children from Birth to 4 Years

28. Medical Costs of RSV-associated Hospitalizations and Emergency Department Visits in Children Aged <5 years: Observational Findings from the New Vaccine Surveillance Network (NVSN), 2016-2019

29. Notes from the Field: Reemergence of Mycoplasma pneumoniae Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018–2024

30. Factors Associated With Prolonged Respiratory Virus Detection From Polymerase Chain Reaction of Nasal Specimens Collected Longitudinally in Healthy Children in a US Birth Cohort

31. Correlates of Rotavirus Vaccine Shedding and Seroconversion in a US Cohort of Healthy Infants

32. Respiratory Syncytial Virus-Associated Hospitalizations Among Children &lt;5 Years Old: 2016 to 2020

33. Cepheid Xpert Xpress Flu/RSV evaluation performed by minimally trained non-laboratory operators in a CLIA-waived environment

34. Respiratory Syncytial Virus-Associated Hospitalizations in Children <5 Years: 2016-2022.

35. Seasonality, Clinical Characteristics, and Outcomes of Respiratory Syncytial Virus Disease by Subtype Among Children Aged <5 Years: New Vaccine Surveillance Network, United States, 2016–2020.

36. Maternal Vaccination and Risk of Hospitalization for Covid-19 Among Infants

37. Clinical Features of Human Metapneumovirus Infection in Ambulatory Children Aged 5–13 Years

38. Data-driven clustering identifies features distinguishing multisystem inflammatory syndrome from acute COVID-19 in children and adolescents

39. 2644. Presence of Respiratory Viruses in the Upper Respiratory Tract of Febrile Infants ≤90 Days Old is Associated with Lower Prevalence of Invasive Bacterial Infection

40. 1755. Hospitalizations for Respiratory Viruses among Children 5–17 Years of Age in the Pre-COVID-19 Pandemic Era, the New Vaccine Surveillance Network, 2016–2020

41. 1103. Endemic Coronavirus Infections in a US Cohort of Children from Birth to 4 Years

42. 1733. Effectiveness of Influenza Vaccination Against Influenza-Associated Emergency Department (ED) Visits and Hospitalizations Among Children With and Without Underlying Medical Conditions, New Vaccine Surveillance Network (NVSN), 2015-2016 through 2019-2020 Influenza Seasons

43. 1752. Seasonal Human Coronavirus in Pediatric Patients enrolled by the New Vaccine Surveillance Network, 2016-2020

44. 1104. Characteristics and Seasonality of Children Hospitalized with Parainfluenza Virus Infections (PIV), including PIV-4, New Vaccine Surveillance Network, 2016–2020

45. 1101. Antiviral Prescription in Children with Influenza in Emergency Departments (ED): New Vaccine Surveillance Network (NVSN), 2016–2020

46. 905. Epidemiology of Enterovirus D68 in the US: New Vaccine Surveillance Network, 2017–2022

47. 650. Antibiotic Use among Children Seeking Medical Care with Acute Gastroenteritis within the New Vaccine Surveillance Network, United States, 2011-2021

48. 1742. Predictors of Antiviral Receipt for Influenza in Hospitalized U.S. Children, New Vaccine Surveillance Network (NVSN), 2016–2020

49. 2622. Recent or concurrent rhino/enterovirus infection with respiratory syncytial virus associated with decreased symptoms and medical care use in healthy children, PREVAIL, 2017–2020

50. 1754. Parainfluenza Virus Co-detection With Respiratory Syncytial Virus or Influenza is Associated with Higher Odds of Hospitalization in Children &lt; 2 Years Old, New Vaccine Surveillance Network (NVSN), 2016–2020

Catalog

Books, media, physical & digital resources